RSS

Genoscience Pharma

Clinical-stage biotech company, Genoscience Pharma, has started administering GNS561 in a Phase I/IIa trial of patients with advanced liver cancer. Read more

News

Genoscience Pharma has announced that initiation of a Phase Ib/IIa study of its most advanced compound, GNS561, for the treatment of patients with advanced hepatocarcinoma (HCC), has received approval from the US Food and Drug Administration (FDA). Read more

News